Limits...
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.

Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J, Brugnara S, Colucci G, Ridolfi R, De Salvo GL, Italian Melanoma Intergroup (IM - Br. J. Cancer (2011)

Bottom Line: No difference in toxicity was observed between the two arms.The incidence of CNS failures in metastatic melanoma was not significantly reduced and the clinical course was not modified substituting a dacarbazine-based regimen with a temozolomide-based regimen.Patients who developed CNS metastases did not have a worse prognosis than patients progressing in other sites and should not be excluded from new investigational studies.

View Article: PubMed Central - PubMed

Affiliation: Melanoma and Skin Cancer Unit, Istituto Oncologico Veneto IOV-IRCCS, via Gattamelata 64, Padova 35128, Italy. mgaliz@tiscali.it

ABSTRACT

Background: This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and a dacarbazine-based regimen in untreated stage IV melanoma patients.

Methods: A total of 150 patients were randomly assigned to receive either oral temozolomide (200 mg m(-2) per day; days 1-5) or intravenous dacarbazine (800 mg m(-2); day 1), in combination with intravenous cisplatin (75 mg m(-2); day 1) and subcutaneous interleukin-2 (3 MU twice daily; days 9-18), every 28 days (CTI and CDI).

Results: A total of 149 patients were eligible for an intention-to-treat analysis (CTI: n=74, CDI: n=75). The 1-year cumulative CNS incidence failure was 20.6% for CTI and 31.1% for CDI (P=0.22). In all 24 patients in CTI (32%) and 34 (45%) in CDI developed CNS metastases; 31 patients died of early systemic progression, before CNS evaluation. Median survival time was 8.4 months in the CTI and 8.7 in the CDI arm; in patients with CNS metastases the median survival time was 13.5 months in the CTI and 11.5 in the CDI arm. No difference in toxicity was observed between the two arms.

Conclusion: The incidence of CNS failures in metastatic melanoma was not significantly reduced and the clinical course was not modified substituting a dacarbazine-based regimen with a temozolomide-based regimen. Patients who developed CNS metastases did not have a worse prognosis than patients progressing in other sites and should not be excluded from new investigational studies.

Show MeSH

Related in: MedlinePlus

Cumulative incidence function of central nervous system failure of patients receiving TMZ-based chemotherapy (CTI) and DTIC-based chemotherapy (CDI).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3111207&req=5

fig2: Cumulative incidence function of central nervous system failure of patients receiving TMZ-based chemotherapy (CTI) and DTIC-based chemotherapy (CDI).

Mentions: Figure 2 shows the cumulative incidence of the CNS metastases among patients treated with CTI and CDI. Death without CNS metastases was considered a competing event. The observed risk of a CNS relapse with CTI was not significantly different to that with CDI (P=0.22, Gray's test).


Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.

Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J, Brugnara S, Colucci G, Ridolfi R, De Salvo GL, Italian Melanoma Intergroup (IM - Br. J. Cancer (2011)

Cumulative incidence function of central nervous system failure of patients receiving TMZ-based chemotherapy (CTI) and DTIC-based chemotherapy (CDI).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3111207&req=5

fig2: Cumulative incidence function of central nervous system failure of patients receiving TMZ-based chemotherapy (CTI) and DTIC-based chemotherapy (CDI).
Mentions: Figure 2 shows the cumulative incidence of the CNS metastases among patients treated with CTI and CDI. Death without CNS metastases was considered a competing event. The observed risk of a CNS relapse with CTI was not significantly different to that with CDI (P=0.22, Gray's test).

Bottom Line: No difference in toxicity was observed between the two arms.The incidence of CNS failures in metastatic melanoma was not significantly reduced and the clinical course was not modified substituting a dacarbazine-based regimen with a temozolomide-based regimen.Patients who developed CNS metastases did not have a worse prognosis than patients progressing in other sites and should not be excluded from new investigational studies.

View Article: PubMed Central - PubMed

Affiliation: Melanoma and Skin Cancer Unit, Istituto Oncologico Veneto IOV-IRCCS, via Gattamelata 64, Padova 35128, Italy. mgaliz@tiscali.it

ABSTRACT

Background: This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and a dacarbazine-based regimen in untreated stage IV melanoma patients.

Methods: A total of 150 patients were randomly assigned to receive either oral temozolomide (200 mg m(-2) per day; days 1-5) or intravenous dacarbazine (800 mg m(-2); day 1), in combination with intravenous cisplatin (75 mg m(-2); day 1) and subcutaneous interleukin-2 (3 MU twice daily; days 9-18), every 28 days (CTI and CDI).

Results: A total of 149 patients were eligible for an intention-to-treat analysis (CTI: n=74, CDI: n=75). The 1-year cumulative CNS incidence failure was 20.6% for CTI and 31.1% for CDI (P=0.22). In all 24 patients in CTI (32%) and 34 (45%) in CDI developed CNS metastases; 31 patients died of early systemic progression, before CNS evaluation. Median survival time was 8.4 months in the CTI and 8.7 in the CDI arm; in patients with CNS metastases the median survival time was 13.5 months in the CTI and 11.5 in the CDI arm. No difference in toxicity was observed between the two arms.

Conclusion: The incidence of CNS failures in metastatic melanoma was not significantly reduced and the clinical course was not modified substituting a dacarbazine-based regimen with a temozolomide-based regimen. Patients who developed CNS metastases did not have a worse prognosis than patients progressing in other sites and should not be excluded from new investigational studies.

Show MeSH
Related in: MedlinePlus